What Are the Most Powerful Immunogen Design Vaccine Strategies?: Reverse Vaccinology 2.0 Shows Great Promise
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Functional antibodies, i.e., those with antipathogen activity in in vitro assays, are generally the best correlate of vaccine protection.Mimics of natural infection, including live attenuated and killed pathogens, which induce such antibodies in vivo, have generated highly successful vaccines.However, pathogens that induce functional antibodies at lower levels or more sporadically have been more refractory to vaccine design.Such pathogens are being tackled by more systematic approaches involving identifying functional antibodies, templating immunogens from the antibodies, and then evaluating the immunogens iteratively.I believe this is a powerful new approach to vaccine design as discussed below. GREAT DEBATESWhat are the most interesting topics likely to come up over dinner or drinks with your colleagues?Or, more importantly, what are the topics that don't come up because they are a little too controversial?In Immune Memory and Vaccines: Great Debates, Editors Rafi Ahmed and Shane Crotty have put together a collection of articles on such questions, written by thought leaders in these fields, with the freedom to talk about the issues as they see fit.This short, innovative format aims to bring a fresh perspective by encouraging authors to be opinionated, focus on what is most interesting and current, and avoid restating introductory material covered in many other reviews.The Editors posed 13 interesting questions critical for our understanding of vaccines and immune memory to a broad group of experts in the field.In each case, several different perspectives are provided.Note that while each author knew that there were additional scientists addressing the same question, they did not know who these authors were, which ensured the independence of the opinions and perspectives expressed in each article.Our hope is that readers enjoy these articles and that they trigger many more conversations on these important topics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus
McLellan, J. S., Chen, M., Joyce, M. G., Sastry, M., Stewart-Jones, G. B. E., Yang, Y., Zhang, B., Chen, L., Srivatsan, S., Zheng, A., et al. (2013) · Science · doi:10.1126/science.1243283 · Cited by 1,126
Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody
McLellan, J. S., Chen, M., Leung, S., Graepel, K. W., Du, X., Yang, Y., Zhou, T., Baxa, U., Yasuda, E., Beaumont, T., et al. (2013) · Science · doi:10.1126/science.1234914 · Cited by 883
Antibodies, viruses and vaccines
Burton, D. R. (2002) · Nature Reviews Immunology · doi:10.1038/nri891 · Cited by 637
Self-citationProof of principle for epitope-focused vaccine design
Correia, B. E., Bates, J. T., Loomis, R. J., Baneyx, G., Carrico, C., Jardine, J. G., Rupert, P., Correnti, C., Kalyuzhniy, O., Vittal, V., et al. (2014) · Nature · doi:10.1038/nature12966 · Cited by 555 · cited 1×
“A second approach is described by Schief and coworkers in which a helix–turn–helix motif from RSV F and recognized by an RSV-neutralizing antibody was generated as a scaffold using computational design methods (Correia et al. 2014).”
Method
Cited by
A systematic review of SARS-CoV-2 vaccine candidates
Dong, Y., Dai, T., Wei, Y., Zhang, L., Zheng, M., & Zhou, F. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00352-y · Cited by 545
Exploitation of glycosylation in enveloped virus pathobiology
Watanabe, Y., Bowden, T. A., Wilson, I. A., & Crispin, M. (2019) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2019.05.012 · Cited by 482
Duan, L., Zheng, Q., Zhang, H., Niu, Y., Lou, Y., & Wang, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.576622 · Cited by 408
Vulnerabilities in coronavirus glycan shields despite extensive glycosylation
Watanabe, Y., Berndsen, Z. T., Raghwani, J., Seabright, G. E., Allen, J. D., Pybus, O. G., McLellan, J. S., Wilson, I. A., Bowden, T. A., Ward, A. B., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16567-0 · Cited by 379
Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies
Haynes, B. F., Wiehe, K., Borrow, P., Saunders, K. O., Korber, B., Wagh, K., McMichael, A. J., Kelsoe, G., Hahn, B. H., Alt, F., et al. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00753-w · Cited by 352
Immunoinformatics and Vaccine Development: An Overview
Oli, A. N., Obialor, W. O., Ifeanyichukwu, M. O., Odimegwu, D. C., Okoyeh, J. N., Emechebe, G. O., Adejumo, S. A., & Ibeanu, G. C. (2020) · ImmunoTargets and Therapy · doi:10.2147/itt.s241064 · Cited by 281
Antibodies to combat viral infections: development strategies and progress
Pantaleo, G., Correia, B., Fenwick, C., Joo, V. S., & Perez, L. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00495-3 · Cited by 279
The science and medicine of human immunology
Pulendran, B., & Davis, M. M. (2020) · Science · doi:10.1126/science.aay4014 · Cited by 274
Passive immunotherapy of viral infections: 'super-antibodies' enter the fray
Walker, L. M., & Burton, D. R. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.148 · Cited by 268
Self-citationDe novo protein design enables the precise induction of RSV-neutralizing antibodies
Sesterhenn, F., Yang, C., Bonet, J., Cramer, J. T., Wen, X., Wang, Y., Chiang, C.-I., Abriata, L. A., Kucharska, I., Castoro, G., et al. (2020) · Science · doi:10.1126/science.aay5051 · Cited by 191
New Vaccine Design and Delivery Technologies
Kanekiyo, M., Ellis, D., & King, N. P. (2019) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiy745 · Cited by 69
Havenar-Daughton, C., Carnathan, D. G., Boopathy, A. V., Upadhyay, A. A., Murrell, B., Reiss, S. M., Enemuo, C. A., Gebru, E. H., Choe, Y., Dhadvai, P., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.10.008 · Cited by 58
“This is essential to iterative design, which is a central tenet of successful engineering processes, instead of depending on “home run” outcomes (Burton, 2017; Kwong, 2017).”
Self-citation
Metadata
- Authors
- Burton, D. R.
- Venue
- Cold Spring Harbor Perspectives in Biology
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2017-02-03
- Volume
- 9
- Issue
- 11
- Pages
- a030262
- ISSN
- 1943-0264 (ISSN-L)
- OpenAlex
- W2585432610
- Cited by
- 133
- References
- 4
- Type
- posted content
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.